gefitinib has been researched along with t0901317 in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (t0901317) | Trials (t0901317) | Recent Studies (post-2010) (t0901317) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 567 | 3 | 330 |
| Protein | Taxonomy | gefitinib (IC50) | t0901317 (IC50) |
|---|---|---|---|
| Chain A, Oxysterols receptor LXR-beta | Homo sapiens (human) | 0.1 | |
| Chain A, Oxysterols receptor LXR-beta | Homo sapiens (human) | 0.1 | |
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | 0.0386 | |
| Nuclear receptor ROR-alpha | Homo sapiens (human) | 2.3 | |
| Presenilin-1 | Homo sapiens (human) | 4.5 | |
| Presenilin-2 | Homo sapiens (human) | 4.5 | |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | 1.6113 | |
| Oxysterols receptor LXR-beta | Homo sapiens (human) | 0.4688 | |
| Oxysterols receptor LXR-alpha | Homo sapiens (human) | 0.0223 | |
| Gamma-secretase subunit APH-1B | Homo sapiens (human) | 4.5 | |
| Nicastrin | Homo sapiens (human) | 4.5 | |
| Nuclear receptor ROR-beta | Homo sapiens (human) | 10 | |
| Gamma-secretase subunit APH-1A | Homo sapiens (human) | 4.5 | |
| Bile acid receptor | Homo sapiens (human) | 5.3 | |
| Gamma-secretase subunit PEN-2 | Homo sapiens (human) | 4.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JW; Jeong, Y; Jung, SH; Kim, HW; Kim, J; Park, KH; Wairagu, PM; Yeh, BI; Yong, SJ | 1 |
| Cao, H; Ding, L; Feng, J; Li, H; Liu, S; Ma, R; Ni, J; Wang, Z; Wu, J; Zhang, XQ; Zhao, X; Zhou, LL | 1 |
| Cao, H; Dong, S; Feng, J; Lou, R; Ma, R; Shi, C; Wu, J; Xu, X | 1 |
3 other study(ies) available for gefitinib and t0901317
| Article | Year |
|---|---|
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin B; Cyclin D1; ErbB Receptors; Gefitinib; Humans; Hydrocarbons, Fluorinated; Indoles; Liver X Receptors; Lung Neoplasms; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Quinazolines; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Sulfones | 2014 |
Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; ATP Binding Cassette Transporter 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; PPAR gamma; Sulfonamides; Thiazolidinediones | 2018 |
Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Female; Gefitinib; Humans; Hydrocarbons, Fluorinated; In Vitro Techniques; Liver X Receptors; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |